Multicentre SMS Study - FR

NCT06640764 — Recruiting, 260 participants, Medacta International SA

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Étude Prospective, Multicentrique, Non contrôlée, Non randomisée, Ouverte évaluant la Performance et la stabilité de l'Implant fémoral Non cimenté SMS

RegistryNCT06640764
StatusRecruiting
Study typeObservational
Enrollment260 (Estimated)
SponsorMedacta International SA (Industry)
ConditionsDysplasia of Hip Joint, Hip Osteoarthritis, Traumatic Arthritis of Hip, Avascular Necrosis of Femur Head
InterventionsTotal Hip Arthroplasty (Procedure)
Datesstart 2024-09-01, primary completion 2034-09-01 (estimated), completion 2037-09-01 (estimated), first posted 2024-10-15, last updated 2026-10-08
Locations1 site in France

Related Papers Related Patents Related Grants Related Experts
All trials for Dysplasia of Hip Joint All trials for Hip Osteoarthritis All trials of Total Hip Arthroplasty

-Summary

Prospective, multicentre, non controled, non randomised, clinical study to assess the performance and the stability of SMS femoral stem

Expand all sections  ·  Collapse all

+Arms and interventions

  • Total Hip Arthroplasty (Procedure): Total Hip Arthroplasty with SMS Femoral Stem (Medacta)

+Outcome measures

Primary outcomes

  • Survival rate of SMS femoral stem [From enrollment to the end of treatment at 10 years]: Survival analysis accordin to the Kaplan-Meier method

Secondary outcomes

  • Evaluation of the clinical performance of the SMS femoral stem [From enrollment to the end of treatment at 10 years]: Clinical performance of the SMS femoral stem evaluated through the Harris Hip Score. The Harris Hip Score is a standardized measure used to assess the severity of hip pain and functional limitations in individuals with hip conditions. The maximum score possible is 100. Results can be interpreted with the following: <70 = poor result; 70-80 = fair, 80-90 = good, and 90-100 = excellent.
  • Evaluation of the hip function [From enrollment to the end of treatment at 10 years]: Hip function evaluated through the Oxford Hip Score. The Oxford Hip Score (OHS) is a short 12-item patient-reported PRO specifically designed and developed to assess function and pain with patients undergoing hip replacement surgery. The total gives a minimum score of 12 and a maximum of 60. A higher score implies a greater degree of disability.
  • Evaluation of the quality of life [From enrollment to the end of treatment at 10 years]: Quality of life evaluated through the EuroQol Score (EQ-5D-5L). The EQ-5D family of instruments has been developed to describe and value health across a wide range of disease areas. Each EQ-5D instrument comprises a short descriptive system questionnaire and a visual analogue scale (EQ VAS) that are cognitively undemanding, taking only a few minutes to complete. The questionnaire provides a simple descriptive profile of a respondent's health state. The EQ VAS provides an alternative way to elicit an individual's rating of their own overall current health
  • Evaluation of the safety (adverse events) of the SMS femoral stem [From enrollment to the end of treatment at 10 years]: Safety of the SMS femoral stem evaluated through the collection of the intraoperative and postoperative complications
  • Evaluation of the stability and the fixation of the SMS femoral stem [From enrollment to the end of treatment at 10 years]: Stability and fixation of the SMS femoral stem evaluated through the radiographic anaysis, assessing the position of the implant (subsidence and migration), the presence of radiolucent lines, the implant breakage.

+Eligibility

Sex: All, ages: 18 Years to 85 Years

Inclusion Criteria:

* Patient suffering from a severely painful and/or disabling hip joint due to osteoarthritis, traumatic arthritis, developmental dysplasia of the hip, or avascular necrosis of the femoral head, and requiring a total hip replacement.
* Patient who will receive a Medacta SMS femoral stem.
* Patient agrees to comply with the study requirements.
* Patient has signed the consent form.
* Patient is affiliated with a social security system.
* Patient aged 18 to 75 years

Exclusion Criteria:

* Participation in biomedical research.
* Minor patient.
* Protected adult patient.
* Vulnerable individuals as defined by Article L1121-6 of the Public Health Code.
* Pregnant or breastfeeding women.
* Patient unable to express their non-opposition.
* Patient refusing the collection of their personal data.
* Acute, systemic, or chronic infection. Skeletal immaturity.
* Grossly deformed anatomy (at the surgeon's discretion).
* Osteomalacia for which the fixation of an uncemented implant is contraindicated.
* Patient suffering from active rheumatoid arthritis or osteoporosis.
* Patient with metabolic disorders likely to impair bone formation when the fixation of an uncemented implant is contraindicated.
* Patient suffering from muscle atrophy or neuromuscular disease.
* Patient with an allergy to the implant material.
* Any patient who cannot or does not wish to give their informed consent to participate in the study.
* Patient whose prospects of regaining independent mobility would be compromised by known coexisting medical problems.
* Any contraindication mentioned in the instructions for use of the investigational medical device.

+Locations (1)

FacilityCityCountryStatus
Clinique de l'UnionSaint-JeanFranceRecruiting